Back to search

Synthesis Med Chem (Uk) Limited

07624460

active
ltd
england wales
Companies House
Health Score
90 / 100

Healthy

30/30
Filing
20/30
Financial
40/40
Risk
  • Going concern doubt noted in accounts (-10)

Details

C/O Kingly Jones Llp 414 Linen Hall, 162-168 Regent Street, London, W1B 5TE
Incorporated 06/05/2011

Compliance

Last accounts

31/12/2024

medium

Next accounts due

30/09/2026

On track

Confirmation statement

Last: 12/03/2026

Due 26/03/2027

On track

Industry

72110
Research and experimental development on biotechnology

Officers

Xianyong Bu

director · Since 06/05/2011

Australian · Australia · Age 56

Simon Andrew Bury

director · Since 26/07/2022

British · England · Age 68

Daniel Ning Mao

director · Since 28/08/2023

American · China · Age 37

Former

Barbara Kahan

director · Resigned 06/05/2011

Michael Dyson

director · Resigned 26/11/2012

Nigel Grahame Ramsden

director · Resigned 15/04/2016

Simon Andrew Bury

director · Resigned 21/02/2021

Andrew Frederick Wilks

director · Resigned 26/02/2021

Zhixiong Ye

director · Resigned 28/08/2023

Persons with Significant Control

Former PSCs

Mr Andrew Frederick Wilks

Ceased 26/02/2021

Mr Chen Cheney Mao

Ceased 30/03/2023

Viva Biotech Holdigs Ltd

Ceased 27/02/2026

Change History

statusactive
2026-06-10

Active

typeltd
2026-06-10

Private Limited Company

address line1C/O Kingly Jones Llp 414 Linen Hall
2026-06-10

C/O KINGLY JONES LLP 414 LINEN HALL

post townLondon
2026-06-10

LONDON

officer appointedBU, Xianyong
2026-06-10
officer appointedBURY, Simon Andrew
2026-06-10
officer appointedMAO, Daniel Ning
2026-06-10

CompanyRankvs 846+ SIC 72110 peers
55

Financial strength40th percentile among SIC peers · 10/25
Employees85th percentile among SIC peers · 13/15
LiquidityCurrent ratio 1.03× · 12/20
Longevity15 years trading (max 15) · 15/15
Filing complianceAll filings up to date · 15/15
Going concern doubt -10
Show leaderboard
How is this score calculated?
Financial strength10/25 pts

Net worth compared to all companies in the same SIC code with published accounts. Top quartile earns the full 25 points.

Employees13/15 pts

Workforce size relative to sector peers from the most recent accounts. A larger team generally signals commercial scale.

Liquidity12/20 pts

Current assets ÷ current liabilities. A ratio above 2× earns full marks; between 1–2× scores partially; below 0.5× scores minimal points.

Longevity15/15 pts

One point per year of operation since incorporation, capped at 15. Older companies have a proven track record.

Filing compliance15/15 pts

Full 15 points when both annual accounts and confirmation statement are filed on time. Points are deducted for each overdue filing.

Risk deductions

Going concern doubt: -10 pts

Maximum score is 100. Deductions apply for insolvency history, outstanding charges, going concern doubt, or disqualified officers.

Going Concern Doubt

we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. Our responsibilities and the responsibilities of the directors with respect to going co

Key FinancialsYear ending 31/12/2024

Turnover

£1.3M

Annual revenue

Net Worth

£100

Balance sheet strength

Cash

£1.5M

Cash in the bank

Profit Before Tax

£22k

Bottom line earnings

Net Current Assets

£91k

Working capital

Current Assets

£2.9M

Current Liabilities

£2.8M

Debtors

£1.4M

Cost of Sales

£811k

Gross Profit

£488k

Admin Expenses

£470k

Operating Profit

£18k

Profit After Tax

£17k

5avg. employees+1

Tax at Year End

Corp tax£83

People Costs

Wages & salaries£281k
NI contributions£33k

Balance Sheet

Assets less current liabilities£91k
Prepared with IRIS Accounts Production

EstimatesDerived

YearCurrent Ratio
20241.03
20231.03
20221.02
20211.10
20201.08
20191.04

Derived from filed accounts. Not audited figures.